Cargando…
Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel
BACKGROUND: It is believed that motor symptoms, including dyskinesia, and non-motor symptoms impact health-related quality of life (HRQoL) in patients with Parkinson’s disease (PD), and that improvements in these metrics are correlated. OBJECTIVE: Investigate the relationship between HRQoL and measu...
Autores principales: | Kovács, Norbert, Bergmann, Lars, Anca-Herschkovitsch, Marieta, Cubo, Esther, Davis, Thomas L., Iansek, Robert, Siddiqui, Mustafa S., Simu, Mihaela, Standaert, David G., Chaudhuri, K. Ray, Bourgeois, Paul, Gao, Tianming, Kukreja, Pavnit, Pontieri, Francesco E., Aldred, Jason |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108584/ https://www.ncbi.nlm.nih.gov/pubmed/34974438 http://dx.doi.org/10.3233/JPD-212979 |
Ejemplares similares
-
DUOGLOBE: One‐Year Outcomes in a Real‐World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease
por: Standaert, David G., et al.
Publicado: (2021) -
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
por: Chaudhuri, K. Ray, et al.
Publicado: (2023) -
Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019) -
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on ‘Off’-time in Patients with Advanced Parkinson’s Disease: A Systematic Review
por: Antonini, Angelo, et al.
Publicado: (2021) -
Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa
por: Zadikoff, Cindy, et al.
Publicado: (2020)